Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.47 |
| ▸ | S100A10 | P60903 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 9/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295521 | 1.00 | KDM4E (0.47) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4300216 | 0.88 | KDM4E (0.51) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4300213 | 0.88 | KDM4E (0.51) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4293937 | 0.85 | KDM4E (0.46) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4293939 | 0.85 | KDM4E (0.46) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4298697 | 0.83 | KMT2A (0.47) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4300011 | 0.83 | KDM4E (0.47) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4298698 | 0.83 | KMT2A (0.47) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4300014 | 0.83 | KDM4E (0.47) | KDM4ERXFP1ANXA2S100A10TP53 | |
| SCHEMBL4293908 | 0.81 | RXFP1 (0.62) | KDM4ERXFP1ANXA2S100A10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | claimed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | claimed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | KDM4E 2532/4885RXFP1 1183/4885ANXA2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.